Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Treatments

Modulators of sphingosine-1-phosphate (S1P) receptors have emerged as pivotal oral disease-modifying therapies for relapsing and progressive forms of multiple sclerosis (MS). These small molecules bind selectively to S1P receptor subtypes, notably S1P₁ and S1P₅, and induce receptor internalisation, thereby preventing lymphocyte egress from lymphoid organs and reducing central nervous system (CNS) infiltration. Beyond peripheral immunomodulation, evidence supports direct neuroprotective and anti-inflammatory actions within the CNS, including attenuation of microglial activation, preservation of oligodendrocyte function and maintenance of excitatory–inhibitory synaptic balance. Four agents—fingolimod, siponimod, ozanimod and ponesimod—have received regulatory approval, each differing in receptor selectivity, pharmacokinetic profile and safety monitoring requirements. Clinical trials demonstrate consistent relapse reduction, while real-world data and long-term extension studies confirm sustained efficacy and manageable safety profiles. Attention to cardiac monitoring at initiation, periodic ophthalmic assessment for macular oedema and vigilance for infection risks underpins safe clinical use. As MS research advances towards repairing neurodegenerative processes, CNS-penetrant S1P modulators represent a versatile class capable of combining immunological restraint with potential remyelinating and neuroprotective benefits.

Research from Nature Portfolio

Recent studies have explored the central mechanisms underpinning siponimod’s efficacy in progressive MS models. In experimental autoimmune encephalomyelitis (EAE), siponimod produced dose-dependent clinical improvement, reduced spinal cord demyelination and limited lymphocyte infiltration independent of immune cell expression of brain-derived neurotrophic factor (BDNF). Flow cytometry revealed a shift towards regulatory T cell populations, while immunohistochemistry confirmed attenuation of inflammatory lesions. In vitro assays with dorsal root ganglion neurons demonstrated that supernatants from treated splenocytes reversed overexpression of chemokines CCL2 and CX3CL1, suggesting that siponimod’s neuroprotective effects partially rely on BDNF-mediated pathways. These insights highlight a dual mode of action—peripheral immunosuppression coupled with central neurotrophic support—that may underlie clinical benefits in secondary progressive MS.

Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Treatments publication trend

The graph below shows the total number of articles in sphingosine-1-phosphate receptor modulators in multiple sclerosis treatments across all publications each year (not limited to Nature Index journals).

Technical terms

Sphingosine-1-Phosphate (S1P): A bioactive lipid mediator that regulates lymphocyte circulation and CNS cell signalling.

S1P receptor modulators: Small-molecule drugs that bind S1P receptor subtypes to sequester lymphocytes and modulate neuroinflammatory pathways.

Experimental autoimmune encephalomyelitis (EAE): An animal model of MS used to study immunological and neurodegenerative mechanisms.

Demyelination: The pathological loss of myelin sheaths around axons, leading to impaired nerve conduction.

Brain-Derived Neurotrophic Factor (BDNF): A neurotrophin essential for neuronal survival, plasticity and repair.

References

1. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. Frontiers in Immunology (2023).
2. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review. Annals of Clinical and Translational Neurology (2024).
3. Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models. Scientific Reports (2024).